Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Executive Summary

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

You may also be interested in...



Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis

Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.

Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory

Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog

Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory

Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel